103 related articles for article (PubMed ID: 22329199)
21. The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib.
Li RC; Zheng LJ; Fang MH; Yu SY
Int J Biol Markers; 2014 Jun; 29(2):e112-9. PubMed ID: 24425324
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS
J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary toxicity associated with erlotinib.
Liu V; White DA; Zakowski MF; Travis W; Kris MG; Ginsberg MS; Miller VA; Azzoli CG
Chest; 2007 Sep; 132(3):1042-4. PubMed ID: 17873198
[TBL] [Abstract][Full Text] [Related]
24. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
[TBL] [Abstract][Full Text] [Related]
25. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Pietanza MC; Lynch TJ; Lara PN; Cho J; Yanagihara RH; Vrindavanam N; Chowhan NM; Gadgeel SM; Pennell NA; Funke R; Mitchell B; Wakelee HA; Miller VA
J Thorac Oncol; 2012 Jan; 7(1):219-26. PubMed ID: 22011666
[TBL] [Abstract][Full Text] [Related]
26. An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer.
Toh CK; Lee P; Chowbay B; Goh JW; Mancer K; Tan PH
Acta Oncol; 2007; 46(2):256-8. PubMed ID: 17453379
[No Abstract] [Full Text] [Related]
27. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
[TBL] [Abstract][Full Text] [Related]
28. Follicular rash during therapy with erlotinib (Tarceva).
Gerdes S; Mrowietz U
J Dtsch Dermatol Ges; 2006 Oct; 4(10):855-7. PubMed ID: 17010175
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
30. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Sugiyama E; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Tsuboi M; Ohe Y; Goto K
Lung Cancer; 2015 Nov; 90(2):307-13. PubMed ID: 26323212
[TBL] [Abstract][Full Text] [Related]
31. Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.
Fiala O; Pesek M; Finek J; Krejci J; Bortlicek Z; Benesova L; Minarik M
Neoplasma; 2013; 60(2):129-34. PubMed ID: 23259780
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Motoshima K; Nakamura Y; Sano K; Ikegami Y; Ikeda T; Mizoguchi K; Takemoto S; Fukuda M; Nagashima S; Iida T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1299-1304. PubMed ID: 24121455
[TBL] [Abstract][Full Text] [Related]
33. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
34. Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
Uruga H; Moriguchi S; Takahashi Y; Ogawa K; Murase K; Mochizuki S; Hanada S; Takaya H; Miyamoto A; Morokawa N; Kishi K
BMC Cancer; 2018 Aug; 18(1):825. PubMed ID: 30115025
[TBL] [Abstract][Full Text] [Related]
35. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
Kawamura T; Hata A; Takeshita J; Fujita S; Hayashi M; Tomii K; Katakami N
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1261-6. PubMed ID: 25921002
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
37. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
38. Erlotinib or gefitinib for non-small-cell lung cancer.
Kaye FJ; Jantz MA; Dallas J
N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675909
[No Abstract] [Full Text] [Related]
39. Unilateral onycholysis in a patient taking erlotinib (Tarceva).
Stevenson R; El-Modir A
BMJ Case Rep; 2011 Aug; 2011():. PubMed ID: 22688477
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]